Kronos Bio Announces Participation in Medical and Investor Conferences in September

Core Insights - Kronos Bio, Inc. is focused on developing small molecule therapeutics targeting deregulated transcription associated with cancers and other diseases [2][3] Upcoming Conferences - Kronos Bio will participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9–11, 2024, in New York, where CEO Norbert Bischofberger will present on September 9 at 2:30 p.m. ET [1] - The company will also present at the American Association for Cancer Research (AACR) 15th Biennial Ovarian Cancer Research Symposium on September 20–21, 2024, in Seattle, with a poster presentation by Luis Carvajal on September 21 [1] - At the International Myeloma Society (IMS) 21st Annual Meeting from September 25–28, 2024, in Rio de Janeiro, Mariateresa Fulciniti will present on the impact of p300 catalytic inhibition on multiple myeloma cell growth on September 28 [1] Company Overview - Kronos Bio is a clinical-stage company with a proprietary discovery engine that decodes transcription factor regulatory networks to identify druggable cofactors [2] - The company has developed a preclinical pipeline and two drug candidates: Istisociclib (KB-0742) targeting CDK9 for MYC deregulation in solid tumors, and KB-9558 targeting p300 for IRF4 dependence in multiple myeloma [2]